HISTORICAL ASPECTS OF THE TREATMENT OF ARTERIAL HYPERTENSION
Abstract
The clinical significance of arterial hypertension (AH) has been known ages ago as well as methods of the treatment. Arterial hypertension therapy has conducted a long evolution, from mechanical methods of lowering blood pressure (BP) such as a bloodletting, the use of various natural and synthetic chemical compounds, to the latest achievements of genetic engineering. The article briefly describes the development of arterial hypertension treatments from antiquity to the nearest future, paying special attention to the latest promising therapies based on genetic engineering methods using small interfering RNAs (siRNAs).
References
World Health Organization. Hypertension. 16 March 2023. Hypertension (high blood pressure) is, get your blood pressure checked. Доступен по: https://www.who.int/news-room/fact-sheets/detail/hypertension#:~:text (дата обращения: 01.06.2024).
Василевский Д.И., Баландов С.Г., Анисимова К.А., Завгородняя М.В. Патогенез артериальной гипертензии (Лекция). Russian Biomedical Research (Российские биомедицинские исследования). 2020;5(3):59–62.
Фоминых Ю.А., Наджафова К.Н., Писаренко А.А., Иванов С.В., Добренко В.А., Иманвердиева Н.А. Артериальная гипертензия у пациентов с ожирением: патогенетические особенности и подходы к коррекции. University Therapeutic Journal. 2024;6(3):87–96. DOI: 10.56871/UTJ.2024.35.74.009.
Глущенко В.А., Ирклиенко Е.К. Сердечно-сосудистая заболеваемость — одна из важнейших проблем здравоохранения. Медицина и организация здравоохранения. 2019;4(1):56–63.
Freis E.D. Historical development of antihypertensive treatment. Chapt. 164 in Hypertension: Pathophysiology, Diagnosis, and Management (2nd Ed.). Ed. by J.H. Laragh and B. M. Brenner. Raven Press. 1995:2741–2751.
Harold J.G. Historical perspectives on hypertension. Cardiology magazine. 2017. Доступен по: https://www.acc.org/latest-in-cardiology/articles/2017/11/14/14/42/harold-on-history-historical-perspectives-on-hypertension (дата обращения: 13.06.2024).
Cameron J.S., Hicks J. Frederick Akbar Mahomed and his role in the description of hypertension at Guy’s Hospital. Kidney International. 1996;49(5):1488–1506. DOI: 10.1038/ki.1996.209.
Beamish R.E., Adamson J.D. Treatment of essential hypertension with sodium thiocyanate. Can Med Assoc J. 1945;53(3):236–42.
Chao-Yin C., Tjen-a-looi S.C. Treating Hypertension: Multiple Approaches to a Common Multifactorial Disease? Austin J Vasc Med. 2014;1(2):1008.
Bishop T., Figueredo V.M. Hypertensive therapy: attacking the renin-angiotensin system. West J Med. 2001;175(2):119–24. DOI: 10.1136/ewjm.175.2.119.
Freis E.D., Wilkins R.W. Effect of pentaquine in patients with hypertension. Proc Soc Exp Biol Med. 1947;64(4):455–8. DOI: 10.3181/00379727-64-15829.
Lyons R.H., Hoobler S.W., Neligh R.B., Moe G.K., Peet M. Experiences with Tetraethylammonium chloride in hypertension. JAMA. 1948;136(9):608–613. DOI: 10.1001/jama.1948.02890260016005.
Paton W.D.M., Zaimis E.J. Paralysis of autonomic ganglia by methonium salts. Brit J Pharmacol. 1951;6:155.
Freis E.D., Rose J.C., Partenope E.A., Higgins T.F., Kelley R.T., Schnaper H.W., Johnson R.L. The hemodynamic effects of hypotensive drugs in man. III. Hexamethonium. J Clin Invest. 1953;32(12):1285–1298. DOI: 10.1172/JCI102857.
Reubi F.C. Renal hyperemia induced in man by a new phthalazine derivative. Proceedings of the Society for Experimental Biology and Medicine. 1950;73(1):102–103. DOI: 10.3181/00379727-73-17591.
Khan M.A. Effect of hydralazine in hypertension. Br Med J. 1953;1:27. DOI: 10.1136/bmj.1.4800.27.
Wilkins R.W., Judson W.E. The use of Rauwolfia serpentina in hypertensive patients. N Engl J Med. 1953;248(2):48–53. DOI: 10.1056/NEJM195301082480202.
Griebenow R., Pittrow D.B., Weidinger G., Mueller E., Mutschler E., Welzel D. Low-dose reserpine/thiazide combination in first-line treatment of hypertension: efficacy and safety compared to an ACE inhibitor. Blood Press. 1997;6(5):299–306. DOI: 10.3109/08037059709062086.
Sprague J. Thiazide Diuretics (Chlorothiazide). Доступен по: https://www.invent.org/inductees/james-sprague (дата обращения: 13.06.2024).
Kirkendall W.M. Clinical evaluation of chlorothiazide. Circulation. 1959;19(6):933–41. DOI: 10.1161/01.cir.19.6.933.
Преображенский Д.В., Сидоренко Б.А., Маренич А.В., Шатунова, И.М. Диуретики в лечении артериальной гипертензии: место гидрохлортиазида. Артериальная гипертензия. 2005;11(2):94–97.
Кобалава Ж.Д., Котовская Ю.В., Виллевальде С.В., Амирбегишвили И.М., Соловьева А.Е. Перспективы лечения артериальной гипертонии. Артериальная гипертензия. 2013;19(4):280–289. DOI: 10.18705/1607-419X-2013-19-4-280-289.
Леонова М.В., Алимова Э.Э., Еремина Ю.Н. Эволюция антагонистов минералокортикоидных рецепторов: эплеренон и спиронолактон. Consilium Medicum. 2017;19(10):60–65. DOI: 10.26442/2075-1753_19.10.60-65.
Подзолков В.И., Драгомирецкая Н.А. Антагонисты альдостерона. Современные представления о механизмах действия и эффектах спиронолактона. Рациональная фармакотерапия в кардиологии. 2017;13(2):263–269.
Oates J.A., Gillespie L., Udenfriend S., Sjoerdsma A. Decarboxylase inhibition and blood pressure reduction by alpha-methyl-3,4-dihydroxy-DL-phenylalanine. Science. 1960;131(3417):1890–1. DOI: 10.1126/science.131.3417.1890.
Gupta M., Al Khalili Y. Methyldopa. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023. Доступен по: https://www.ncbi.nlm.nih.gov/books/NBK551671/ (дата обращения: 13.06.2024).
Hamilton M., Kopelman H. Treatment of severe hypertension with methyldopa. Br Med J. 1963;1(5324):151–5. DOI: 10.1136/bmj.1.5324.151.
Stewart K. Minoxidil. Britannica. Доступен по: https://www.britannica.com/topic/minoxidil (дата обращения: 13.06.2024).
Pettinger W.A. Minoxidil and the treatment of severe hypertension. N Engl J Med. 1980;303(16):922–6. DOI: 10.1056/NEJM198010163031607.
Bryan J. How minoxidil was transformed from an antihypertensive to hair-loss drug. Pharmaceutical Journal. 2011;287(7663):137–138.
Cohn J.N., Liptak T.E., Freis E.D. Hemodynamic Effects of Guanethidine in Man. Circulation Research. 1963;12:298–307. DOI: 10.1161/01.RES.12.3.298.
Cumming G.R., Swain B. Guanethidine as the Sole Agent in the Treatment of Hypertension. Can Med Assoc J. 1961;84(4):187–190.
Prichard B.N., Gillam P.M. Use of propranolol (inderal) in treatment of hypertension. Br Med J. 1964;2(5411):725–7. DOI: 10.1136/bmj.2.5411.725.
Baker J.G., Hill S.J., Summers R.J. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends in Pharmacological Sciences. 2011;32(4-2):227–234. DOI: 10.1016/j.tips.2011.02.010.
Acierno L.J., Fye B., Hurst J.W., Worrell L.T. Albrecht Fleckenstein: Father of calcium antagonism. Clinical Cardiology. 2006;27(12):710–711. DOI: 10.1002/clc.4960271213.
Бова А.А., Трисветова Е.Л. История создания и классификация ингибиторов АПФ. Медицинская панорама. 2003;8.
Havelka J., Vetter H., Studer A., Greminger P., Lüscher T., Wollnik S., Siegenthaler W., Vetter W. Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension. Am J Cardiol. 1982;49(6):1467–74. DOI: 10.1016/0002-9149(82)90362-9.
Stoller J.K., Elghazawi A., Mehta A.C., Vidt D.G. Captopril-induced cough. Chest. 1988;93(3):659–61. DOI: 10.1378/chest.93.3.659.
Bhardwaj G. How the antihypertensive losartan was discovered. Expert Opin Drug Discov. 2006;1(6):609–18. DOI: 10.1517/17460441.1.6.609.
Timmermans P.B., Duncia J.V., Carini D.J., Chiu A.T., Wong P.C., Wexler R.R., Smith R.D. Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens. 1995;9(Suppl.5):S3–18.
Barreras A., Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent). 2003;16(1):123–6. DOI: 10.1080/08998280.2003.11927893.
Scriabine A. 6.32 - Hypertension. Comprehensive Medicinal Chemistry II. 2007;705–728. DOI: 10.1016/B0-08-045044-X/00194-2.
Coats A.J. Omapatrilat — the story of Overture and Octave. Int J Cardiol. 2002;86(1):1–4. DOI: 10.1016/s0167-5273(02)00389-3.
Dana H., Chalbatani G.M., Mahmoodzadeh H., Karimloo R., Rezaiean O., Moradzadeh A., Mehmandoost N., Moazzen F., Mazraeh A., Marmari V., Ebrahimi M., Rashno M.M., Abadi S.J., Gharagouzlo E. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci. 2017;2:48–57.
Khan R.S., Frishman W.H. Zilebesiran: A promising antihypertensive therapy inhibiting angiotensinogen synthesis. Cardiol Rev. 2024. DOI: 10.1097/CRD.0000000000000645.
Desai A.S., Webb D.J., Taubel J., Casey S., Cheng Y., Robbie G.J., Foster D., Huang S.A., Rhyee S., Sweetser M.T., Bakris G.L. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228–238. DOI: 10.1056/NEJMoa2208391.
Bakris G.L., Saxena M., Gupta A., Chalhoub F., Lee J., Stiglitz D., Makarova N., Goyal N., Guo W., Zappe D., Desai A.S. KARDIA-1 Study Group. RNA Interference with zilebesiran for mild to moderate hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024;331(9):740–749. DOI: 10.1001/jama.2024.0728.
Zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications (KARDIA-3) (KARDIA-3). Доступен по: https://www.clinicaltrials.gov/study/NCT06272487 (дата обращения: 13.06.2024).
Zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard of care antihypertensive medication (KARDIA-2). Доступен по: https://classic.clinicaltrials.gov/ct2/show/record/NCT05103332?view=record (дата обращения: 13.06.2024).
Bavry A.A. Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension — KARDIA-2. American college of cardiology. 2024. Доступен по: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2024/04/05/04/26/kardia-2 (дата обращения 11.06.2024).
